mgd014
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03570918)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E inhibitor
- Human immunodeficiency virusImmunity, passive
Human immunodeficiency virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07217379 | Phase 1 | Oct 31, 2025 | Department of Defense, Henry M. Jackson Foundation for the Advancement of Military Medicine, National Institute of Allergy and Infectious Diseases (NIAID), United States Army, University of North Carolina at Chapel Hill |
| NCT05261191 | Phase 1 | Sep 26, 2022 | Department of Health and Human Services, MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT03570918 | Phase 1 | Sep 30, 2018 | MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 0 | 1 | 2018 |
| MacroGenics | For profit | 2 | 2 | 1 | 2018 |
| Department of Defense | Government | 1 | 0 | 1 | 2025 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2022 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 0 | 1 | 2025 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| United States Army | Government | 1 | 0 | 1 | 2025 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1